Skip to main content
CBDY
OTC Life Sciences

Target Group Reports Substantial Doubt About Going Concern, Ineffective Controls, and Worsening Financials

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$0.002
Mkt Cap
$1.111M
52W Low
$0.001
52W High
$0.003
Market data snapshot near publication time

summarizeSummary

Target Group Inc. reported substantial doubt about its ability to continue as a going concern, ineffective internal controls, and a significant worsening of financial performance, relying on high-interest related party debt.


check_boxKey Events

  • Substantial Doubt About Going Concern

    The company's continuation as a going concern is dependent on generating sufficient cash flows or obtaining additional financing, raising substantial doubt about its ability to continue operations.

  • Ineffective Disclosure Controls

    Management concluded that disclosure controls and procedures were not effective as of March 31, 2026.

  • Significant Financial Deterioration

    Revenue declined from $1.4 million in Q1 2025 to $879,442 in Q1 2026, and net loss increased from $108,213 to $550,356 over the same period. The working capital deficit worsened to $11.3 million.

  • High-Interest Related Party Loan

    The company secured a new CDN$330,000 (approximately $236,742 USD) loan from a related party at a high interest rate of 43.26% per annum, with an option for an additional CDN$500,000.


auto_awesomeAnalysis

Target Group Inc. filed its quarterly report for Q1 2026, raising substantial doubt about its ability to continue as a going concern. Management also concluded that the company's disclosure controls and procedures were ineffective. Financially, the company experienced a significant decline in revenue and a substantial increase in net loss compared to the prior year. The working capital deficit worsened, and the company continues to rely on high-interest related party loans, including a new CDN$330,000 advance at 43.26% interest. The reclassification of a $7.4 million related party loan to current liabilities further highlights immediate liquidity pressures. These issues collectively indicate severe financial distress and significant operational risks for the micro-cap company.

At the time of this filing, CBDY was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $0.00 to $0.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed CBDY - Latest Insights

CBDY
May 15, 2026, 4:58 PM EDT
Filing Type: 10-Q
Importance Score:
9
CBDY
Mar 31, 2026, 4:55 PM EDT
Filing Type: 10-K
Importance Score:
9